Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.97, $0.30 better than the analyst estimate of $0.67. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $26.45 million.

GUIDANCE:

Ligand Pharma sees FY2016 EPS of $3.41-$3.46, versus the consensus of $3.37. Ligand Pharma sees FY2016 revenue of $115-119 million, versus the consensus of $118.5 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.